Kala Pharmaceuticals to Present at the Jefferies 2020 Virtual London Healthcare Conference
November 11 2020 - 8:00AM
Business Wire
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical
company focused on the discovery, development and commercialization
of innovative therapies for diseases of the eye, today announced
that it will present at the Jefferies 2020 Virtual London
Healthcare Conference. Mark Iwicki, Chairman and Chief Executive
Officer of Kala Pharmaceuticals, is scheduled to participate in a
fireside chat on Tuesday, November 17, 2020 at 2:05 p.m. GMT (9:05
a.m. ET).
To access a live webcast and subsequent archived recording of
the presentation, please visit the “Events” in the “Investors”
section of the Kala website at http://kalarx.com
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the discovery,
development, and commercialization of innovative therapies for
diseases of the eye. Kala has applied its AMPPLIFY® mucus
penetrating particle Drug Delivery Technology to a corticosteroid,
loteprednol etabonate (LE), designed for ocular applications,
resulting in the October 2020 approval of EYSUVISTM (loteprednol
etabonate ophthalmic suspension) 0.25% for the short-term (up to
two weeks) treatment of signs and symptoms of dry eye disease and
the January 2019 launch of INVELTYS® (loteprednol etabonate
ophthalmic suspension) 1% for the treatment of post-operative
inflammation and pain following ocular surgery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201111005050/en/
Investors: Loraine Spreen loraine.spreen@kalarx.com
857-277-4842 Hannah Deresiewicz hannah.deresiewicz@sternir.com
212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2024 to Jun 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2023 to Jun 2024